PB2512: SAFETY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE: INTEGRATED POST-MARKETING SURVEILLANCE ANALYSIS

• Miguel Abboud,
• Julie Kanter,
• Kwaku Marfo,
• Charmaine Anthony,
• Jeremie Lincy,
• Michele Nassin,
• Vikas Joshi,
• Andreas Brueckner,
• Deborah Keefe,
• Kenneth I. Ataga

Affiliations

Miguel Abboud

1 American University of Beirut Medical Center, Beirut, Lebanon

Julie Kanter

2 University of Alabama-Birmingham, Birmingham, United States

Kwaku Marfo

3 Novartis Pharma AG, Basel, Switzerland

Charmaine Anthony

4 Novartis Pharmaceuticals Corporation, East Hanover, United States

Jeremie Lincy

3 Novartis Pharma AG, Basel, Switzerland

Michele Nassin

4 Novartis Pharmaceuticals Corporation, East Hanover, United States

Vikas Joshi

5 Novartis Healthcare Private Limited, Hyderabad, India

Andreas Brueckner

3 Novartis Pharma AG, Basel, Switzerland

Deborah Keefe

4 Novartis Pharmaceuticals Corporation, East Hanover, United States

Kenneth I. Ataga

6 University of Tennessee Health Science Center, Memphis, United States